Zoetis (NYSE: ZTS) posted a third-quarter earnings beat sharp enough to lift full-year adjusted EPS guidance. Adjusted diluted EPS of $1.75 landed $0.24 above consensus, up 3% year-over-year on operating discipline and a smaller share count. Revenue of $2.39 billion slipped 1% from the prior year and missed by about $31 million, though it cleared estimates by roughly $78 million.
The beat is real. It is also narrow.
Revenue growth was negative. The EPS outperformance came from cost control and buybacks, not top-line acceleration. That distinction matters for the forward look.
Full-year adjusted EPS guidance moved to $6.25-$6.35 from $6.15-$6.25, a roughly 2% lift at the midpoint. Revenue guidance narrowed to $9.22-$9.32 billion from $9.12-$9.32 billion, raising the floor while leaving the ceiling untouched. The move signals some confidence in the second half, but management's refusal to lift the top end suggests limited upside from here. Adjusted net income guidance rose to $2.60-$2.64 billion from $2.57-$2.62 billion, with the organic operational growth range tightening to -7% to -5% from -9% to -5%. The low end moved up three points; the high end held.
Management also cut adjusted R&D expense guidance to $705-$715 million from $720-$730 million and trimmed the effective tax rate assumption to ~20.0% from ~20.5%. Those two items alone explain much of the EPS guidance improvement. The R&D reduction isn't a pipeline red flag: the company announced several regulatory approvals during the quarter, including FDA approval of Convenia RTU for Dogs ahead of schedule. Still, it shows management prioritizing near-term earnings power over R&D spend growth while revenue remains under pressure.
The U.S. companion animal segment is the clear weak link. Revenue fell 8% year-over-year to $980 million, hit by macro-driven price sensitivity, competitive pressure in dermatology, and generic competition. This marks the second consecutive quarter of U.S. companion animal decline, and commentary suggests the pressure is structural, not seasonal. Pet owners are trading down or delaying visits. Zoetis is losing share in dermatology.
The livestock business tells a different story. U.S. livestock grew 5%, while international livestock rose 9% organically, led by cattle, swine, and poultry. International revenue climbed 4% overall, with China up 20%, Australia up 13%, and Brazil up 9%.
An $89 million impairment of PetMedix in-process R&D assets, booked in GAAP results, served as a reminder that not every pipeline bet works. The charge pushed GAAP diluted EPS to $1.44, down 12% year-over-year. Adjusted net income of $720 million fell 5% reported and 7% on an organic operational basis. The gap between GAAP and adjusted results is widening, driven by restructuring charges and the impairment.
The buyback is doing real work. Weighted-average diluted shares fell to 411.6 million from 443.2 million a year ago, a 7% reduction. That alone added roughly $0.12 to EPS year-over-year. At about 22x trailing adjusted earnings, the buyback is accretive. It is also masking underlying earnings decline. Adjusted net income fell 5% reported; without the share count reduction, adjusted EPS would have been flat to slightly down.
The forward read is mixed. The guidance raise is constructive, but driven by cost discipline and tax optimization, not revenue acceleration. The U.S. companion animal drag shows no sign of easing, and competitive pressure in dermatology is intensifying. International livestock is strong, though it contributes from a smaller margin pool. The innovation pipeline is active, with Convenia RTU, Lenivia, and Portela launches expanding the portfolio, but these products need time to move the needle. For Zoetis, the question is whether cost cuts and buybacks can sustain EPS growth until the top line recovers. This quarter suggests they can. Barely.